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Abstract
Efforts to identify and annotate cancer driver genetic lesions have been almost exclusively focused 
on the analysis of protein coding genes. Here we identify a new long-range acting MYC enhancer 
controlled by NOTCH1, targeted by recurrent chromosomal duplications in human T-cell acute 
lymphoblastic leukemia (T-ALL). This highly conserved regulatory element, hereby named N-Me 
for NOTCH MYC enhancer, is located within a broad super-enhancer region +1.47 Mb from the 
MYC transcription initiating site, interacts with the MYC proximal promoter and induces 
orientation-independent MYC expression in reporter assays. Moreover, analysis of N-Me knockout 
mice demonstrates a selective and essential role of this regulatory element during thymocyte 
development and in NOTCH1-induced T-ALL. Altogether, these results identify N-Me as a long 
range oncogenic enhancer directly implicated in the pathogenesis of human leukemia and 
highlight the fundamental importance of the NOTCH1-MYC regulatory axis in T-cell 
transformation and as therapeutic target in T-ALL.
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T-ALL is an aggressive hematologic malignancy resulting from the transformation of 
immature T-cell progenitor cells1 in which activation of transcription factor oncogenes and 
deregulation of transcriptional regulatory networks play particularly prominent roles1–5. In 
this context, activating mutations in the NOTCH1 ligand-activated transcription factor 
oncogene are found in over 60% of human T-ALLs6,7. Mechanistically, NOTCH1 mutations 
found in T-ALL result in high levels of NOTCH1 signaling, which promotes T-cell 
transformation by hijacking physiologic functions of the NOTCH1 receptor in the thymus, 
where ligand-induced NOTCH signaling drives hematopoietic progenitors into the T-cell 
lineage and promotes thymocyte development7–9. Both physiologic and oncogenic effects of 
NOTCH1 require translocation of the intracellular portion of the NOTCH1 receptor to the 
nucleus where it activates gene expression in association with the RBPJ DNA binding 
protein7,10,11. Gene expression studies have identified NOTCH1 as a key regulator of cell 
growth in T-ALL lymphoblasts directly controlling numerous genes involved in cell growth 
and metabolism12. The importance of understanding the hierarchy of the oncogenic 
NOTCH1 transcriptional programs is highlighted by the proposed role of small molecule γ-
secretase inhibitors, which block the release of intracellular NOTCH1 from the membrane 
and effectively suppress NOTCH signaling, as targeted therapies for the treatment of T-
ALL7.
Over the last years, numerous studies have dissected the mutational landscape of T-ALL 
resulting in the identification of numerous oncogenes and tumor suppressors implicated in 
T-cell transformation1,4,13. However, and most intriguingly, most genetic abnormalities 
found in human cancer are located in intergenic regions14, whose role in cancer 
development, if any, remains poorly understood. Here we hypothesized that recurrent 
cancer-associated intergenic mutations, amplifications and deletions may implicate strong 
transcriptional regulatory sequences responsible for the activation of oncogenic factors 
downstream of key T-ALL transcription factor oncogenes such as NOTCH1.
RESULTS
Amplification of a MYC NOTCH1-occupied enhancer in T-ALL
To assess the role of intergenic copy number alterations in the pathogenesis of T-ALL we 
analyzed array comparative genomic hybridization data from 160 T-ALL cases. This 
analysis identified recurrent focal duplications at chromosome 8q24 in 8/160 (5%) T-ALL 
cases in an area devoid of protein-coding genes located +1,427 kb downstream of MYC (Fig. 
1a), a critical oncogene in the pathogenesis of NOTCH1-induced T-ALL12,15,16 (Fig. 1a, 
Supplementary Fig. 1 and Supplementary Tables 1–2). Notably, no duplications in this 
region were identified in 258 non T-ALL hematologic tumors and no germline copy number 
variant polymorphisms encompassing this area have been reported. Moreover, analysis of 
normal (remission) DNA confirmed the somatic origin of these copy number alterations in 
all 4 cases with available material (Supplementary Fig. 1). Interestingly, chromatin 
immunoprecipitation (ChIP) followed by next generation sequencing (ChIP-seq) analysis of 
NOTCH1 chromatin binding sites in HPB-ALL T-ALL cells revealed a prominent 1 kb 
NOTCH1 peak in chromosome 8q24 located within the common 40 Kb segment duplicated 
in all these eight leukemia cases (Fig. 1a). A survey of NOTCH1 and RBPJ ChIP-seq data 
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generated in the CUTLL1 T-ALL cell line17 confirmed the presence of high levels of 
NOTCH1 and RBPJ binding in this site (Fig. 1b and Supplementary Fig. 2). Notably, 
multispecies DNA sequence alignment revealed remarkable conservation of this region in 
mammals, birds and reptiles (Fig. 1b), with 88.6% nucleotide identity between the 500 base 
pair human and mouse sequences centered on the NOTCH1 peak, compared with an average 
conservation of 44% nucleotide identity along the 1.4 Mb gene desert telomeric to MYC. 
Consistently, analysis of NOTCH1 ChIP-seq data in G4A2 mouse T-ALL cells18,19 revealed 
matching NOTCH1 and RBPJ binding peaks located +1,27 Mb from the Myc transcription 
initiation site (Fig. 1c and Supplementary Fig. 2).
To functionally characterize the potential role of this NOTCH1 binding site in gene 
regulation, we performed local ChIP analysis of chromatin regulatory factors and epigenetic 
histone marks in HPB-ALL T-ALL cells. These analyses confirmed high levels of NOTCH1 
binding at this site and revealed bona fide active enhancer features associated with this 
region including P300 occupancy and high levels and H3K4 monomethylation (H3K4me1) 
with low levels of H3K4 trimethylation (H3K4me3) (Fig. 1d and Supplementary Fig. 3). 
Moreover, inspection of ENCODE data in this region revealed that this NOTCH1 occupied 
enhancer sits within a 20 kb segment containing high levels of H3K27 acetylation and H3K4 
monomethylation (Fig. 1e), features characteristically associated with highly dynamic long-
range superenhancer regulatory sequences20. In addition, extended examination of 
ENCODE data revealed that H3K27 acetylation in this area is selectively present in the 
DND-41 cells, a T-ALL cell line harboring a highly active mutant form of NOTCH16, but 
not in primary CD20+ B cells or in cell lines derived from a variety of other hematopoietic 
and non-hematopoietic tissues and cell lines (Fig. 1f and Supplementary Fig. 3).
Based on these results, we proposed that this +1,4 Mb MYC NOTCH1-occupied enhancer –
hereby named N-Me for NOTCH-bound MYC enhancer– could function as an important 
regulatory element driving the activation of MYC downstream of NOTCH1 in T-ALL. 
Consistent with this hypothesis, chromatin configuration 3C analysis of the MYC locus 
demonstrated the association of this enhancer with proximal regulatory sequences in the 
MYC promoter (Fig. 2a). Moreover, luciferase reporter assays showed strong, orientation-
independent activation of reporter constructs containing this enhancer in association with a 
−2.5 kb MYC proximal promoter21 in JURKAT T-ALL cells, which express high levels of 
constitutively active NOTCH1 protein 22, but not in Daudi and Raji B-cell lineage cells (Fig. 
2b and Supplementary Fig. 4). In addition, human N-Me driven reporter activity in 
JURKAT cells was effectively suppressed upon inhibition of NOTCH1 signaling with the 
DBZ γ-secretase inhibitor and decreased upon mutation of N-Me RBPJ binding sites (Fig 
2b,c and Supplementary Fig. 5). Conversely, reporter activity in these assays was increased 
by the introduction of two tandem copies of the human N-Me enhancer demonstrating 
quantitative, dose dependent increase of MYC promoter activity by this regulatory sequence 
(Fig. 2d). Similar results were obtained in reporter assays testing the activity and NOTCH 
signaling dependency of the mouse N-Me enhancer (Fig. 2e,f and Supplementary Fig. 5). 
Overall, these results identify the N-Me enhancer as a recurrently duplicated long-range 
regulatory element involved in the control of MYC expression downstream of NOTCH1 in 
T-ALL.
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The N-Me enhancer is required for thymocyte development
Next, and to test the specificity and functional relevance of the N-Me enhancer in T-cell 
development and transformation, we used homologous recombination in mouse embryonic 
stem cells to generate N-Me knockout and conditional knockout mice (Supplementary Fig. 
6). N-Me knockout (N-Me−/−) mice were born with mendelian frequencies (Supplementary 
Table 3), survived perinatally and showed normal postnatal development without apparent 
behavioral abnormalities or defects in body size (Supplementary Fig. 7). Notably, 
anatomical and histological analysis of mice at 6 weeks of age revealed marked selective 
reduction in thymus size and cellularity in N-Me knockout animals compared to littermate 
controls (Fig. 3a–d). Interestingly, and despite preservation of thymus size and architecture, 
thymocyte counts were partially reduced in N-Me heterozygous knockout mice (Fig. 3a–d). 
Mechanistically, immunohistochemical analysis of N-Me knockout thymi showed marked 
reductions in proliferation markers (Ki67 and phospho-histone H3) with no apparent 
increase in apoptosis (cleaved caspase 3) (Fig. 3e). In addition, analysis of T cell populations 
in spleen and lymph nodes of N-Me knockout animals showed a marked reduction in the 
number mature CD4 and CD8 T cells (Supplementary Fig. 7). Analysis of bone marrow 
hematopoietic populations revealed normal numbers of B-cell precursors, myeloid 
progenitors, megakaryocytes and hematopoietic stem cells (Supplementary Fig. 7). 
Moreover, histological analysis of multiple tissues including those in which NOTCH 
signaling plays important developmental roles such as breast epithelium, skin, and intestine 
showed no alterations (Supplementary Fig. 7) and RT-PCR analysis showed no effects of N-
Me deletion in Myc expression (Supplementary Fig. 7).
Detailed immunophenotypic analysis of thymic populations in N-Me knockout mice 
demonstrated accumulation of double negative 3 (DN3) T cells and marked reductions in 
double positive and CD4+ and CD8+ single positive cells (Fig. 4a–e). Mechanistically, this 
phenotype was associated with a marked reduction in Myc expression in DN3, DN4 and 
intermediate single positive cells (Fig. 4f). Consistently, transplantation of CD45.2 N-Me 
knockout bone marrow hematopoietic progenitors into lethally irradiated CD45.1 mice 
effectively reconstituted B-cell and myeloid lineages, but not T-cell development (Fig. 4g). 
Moreover, retroviral expression of MYC in N-Me knockout hematopoietic progenitors 
restored their capacity to restore T-cell development when transplanted into 
immunodeficient NRG mice (Fig. 4h).
N-Me is required for NOTCH1-induced T-cell leukemogenesis
Given the important role of NOTCH1 induced MYC upregulation in the pathogenesis of T-
ALL, we hypothesized that deletion of the N-Me enhancer could disrupt NOTCH1 induced 
leukemogenesis. To test this possibility we transplanted isogenic C57Bl6 mice with N-Me 
wild type, heterozygous and homozygous knockout hematopoietic progenitors infected with 
retroviruses driving the expression of an oncogenic constitutively active form of NOTCH1 
(ΔE-NOTCH1)10. Consistent with previous reports23, mice transplanted with ΔE-NOTCH1 
infected N-Me wild type cells showed a transient wave of CD4 CD8 double positive cells in 
peripheral blood three weeks post-transplant (Fig. 5a), which anticipated the development of 
overt T-ALL 3 weeks later (Fig. 5b,c). Mice transplanted with ΔE-NOTCH1-expressing N-
Me heterozygous progenitors showed a blunted CD4 CD8 double positive cell wave and 
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delayed tumor development (P <0.01) (Fig. 5a–c), while animals transplanted with ΔE-
NOTCH1 N-Me knockout cells failed to develop a CD4 CD8 double positive wave and 
remained leukemia free 9 weeks post-transplant (P <0.001)(Fig. 5a–c).
Next, and to explore the pathogenic role of N-Me-mediated Myc expression in NOTCH 
induced leukemia tumor maintenance, we generated ΔE-NOTCH1-induced T-ALL tumors 
from N-Me wild type (Rosa26TMCre N-Me+/+) and tamoxifen-inducible conditional 
heterozygous (Rosa26TMCre N-Meflox/+) and homozygous (Rosa26TMCre N-Meflox/flox) 
N-Me knockout hematopoietic progenitors as before. In these experiments, mice 
transplanted with ΔE-NOTCH1-expressing N-Me wild type and tamoxifen-inducible 
heterozygous and homozygous conditional N-Me knockout cells developed NOTCH1-
induced T-ALLs with identical kinetics and immunophenotype (Supplementary Fig. 8). To 
test the effects of N-Me deletion in these established leukemias we then injected N-Me wild 
type and tamoxifen-inducible heterozygous and homozygous conditional N-Me knockout T-
ALL lymphoblasts into secondary recipients and treated them with vehicle only or 
tamoxifen three days after transplant. In these experiments tamoxifen-induced activation of 
Cre recombinase had no effect in leukemia progression in mice harboring N-Me wild type 
tumor cells compared with controls (Fig. 6a). In contrast, tamoxifen-induced deletion of one 
copy of the N-Me enhancer in Rosa26TMCre N-Meflox/+ tumors or two copies in 
Rosa26TMCre N-Meflox/flox leukemias resulted in overt antileukemic effects and improved 
survival (Fig. 6b,c). Interestingly, analysis of Rosa26TMCre N-Meflox/+ tumor cells 
recovered upon disease progression after tamoxifen treatment showed heterozygous deletion 
of the N-Me enhancer (Supplementary Fig. 9), while analysis of tamoxifen-treated 
progressing Rosa26TMCre N-Meflox/flox tumors demonstrated retention of one (2/9) or both 
(5/9) copies of the N-Meflox allele (Supplementary Fig. 9). Finally, we performed limited 
dilution transplantations of conditional NOTCH1-induced N-Me knockout tumor cells and 
analyzed the effects N-Me inactivation via tamoxifen treatment in leukemia initiating cell 
activity. In this experiment, genetic inactivation of the N-Me enhancer resulted in a ~170 
fold reduction in leukemia initiating cell frequency (Supplementary Fig. 10). Overall these 
results show a strong dose dependent effect of the N-Me enhancer in NOTCH1-induced 
tumor initiation and maintenance and in leukemia initiating cell activity.
To better assess the mechanisms mediating the antileukemic effects of N-Me inactivation we 
then analyzed the cellular and transcriptional phenotypes of N-Me conditional inducible 
knockout T-ALL cells after tamoxifen treatment. In this setting, N-Me deletion in T-ALL 
cells (Supplementary Fig. 11) resulted in unloading of RNA polymerase II from the Myc 
transcription start site (Fig. 6d) and markedly reduced Myc RNA and protein expression 
levels (Fig. 6e,f). At the cellular level N-Me inactivation caused decreased cell proliferation 
with G1 cell cycle arrest (Fig. 6g). Notably, retroviral expression of MYC rescued the 
growth defect associated with genetic deletion of N-Me in NOTCH1-driven N-Me 
conditional knockout tumor cells (Fig 6h). Finally, gene expression profiling analysis 
showed that N-Me inactivation results in effective downregulation of Myc induced gene 
expression programs (Fig. 6i,j) and of gene expression signatures associated with cell 
growth and proliferation (Supplementary Table 4).
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DISCUSSION
NOTCH1 plays a central role in the pathogenesis of T-ALL24 and drives an oncogenic 
transcriptional program that promotes cell growth proliferation and survival in T-ALL 
lymphoblasts. Importantly, the oncogenic effects of NOTCH1 are closely linked to 
activation of the MYC oncogene12,15,16. Thus, NOTCH1 activation upregulates MYC 
expression in T-ALL and NOTCH1 and MYC have been shown to regulate overlapping 
transcriptional programs in a feed-forward loop transcriptional circuitry that amplifies the 
oncogenic effects of NOTCH112. However, the specific mechanisms that drive MYC 
expression downstream of NOTCH1 in TALL remain incompletely understood. Here we 
report the identification and functional characterization of N-Me, a T-cell specific long-
range regulatory sequence driving MYC expression downstream of NOTCH1 in T-ALL. 
This regulatory element, located +1,427 kb downstream of MYC in humans and +1.27 Kb 
downstream of the Myc locus in mice, has histone marks associated with active enhancers, 
interacts with MYC proximal regulatory sequences and sits within a broad area of H3K27 
acetylation recently characterized as a T-cell specific super-enhancer25.
Transcriptional deregulation of MYC expression plays an important role in the pathogenesis 
of multiple cancers and the chromosome 8q24 region proximal to the MYC gene is a well 
established risk locus for epithelial tumors26–30. Most of the genetic variants associated with 
cancer risk at 8q24 are located in a 500 kb gene desert region located approximately 200 kb 
centromeric of the MYC gene. This region contains multiple enhancer regulatory 
sequences31, which physically associate the MYC promoter via long range chromatin 
loops32. Most notably, rs6983267, an enhancer-associated colon cancer risk allele variant in 
this region, has been shown to influence MYC expression downstream of beta-catenin-
TCF433. Moreover, genetic deletion of the enhancer containing this regulatory element in 
the gut results in partial reduction of Myc expression in intestinal crypts and confers 
protection from intestinal tumorigenesis in APCmin mutant mice34. In contrast, no cancer-
associated single nucleotide variants have been mapped to the larger gene-free region 
telomeric to the MYC gene where N-Me resides. However, a recent report has identified a 
broad regulatory area of about 100 kb located 1.7 Mb telomeric to the Myc gene, 400 kb 
downstream of N-Me35. This Myc regulatory region contains multiple enhancers active in 
myeloid cells, but not thymus, and is duplicated in about 3% of acute myeloid leukemias35.
Genetic deletion of N-Me in mice resulted in marked reduced thymic cellularity and cell 
proliferation demonstrating a critical role of this regulatory element in the homeostasis of 
immature T-cells. N-Me null mice showed severe reduction in the number of CD4 CD8 
double positive cells and subsequent single positive CD4 and CD8 populations. These 
phenotypes perfectly recapitulate those reported in T-cell specific Myc conditional knockout 
mice (Lck-Cre Mycf/f)36. Given the proposed role of NOTCH1 signaling in hematopoietic 
stem cells and in non lymphoid tissues such as breast epithelium we thoroughly examined a 
potential role for N-Me in the control of Myc expression in these tissues. However, and 
consistent with a T-cell specific role of N-Me in the control of Myc expression, we detected 
no alterations in any cellular compartment other than T-cells. These results support that as 
yet to be identified NOTCH1 controlled enhancers may regulate Myc expression in breast 
epithelium and hematopoietic stem cells.
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Strikingly, the requirement for N-Me mediated upregulation of Myc expression downstream 
of Notch1 was even more patent in the context of leukemia initiation, where loss of one and 
two copies of N-Me delayed and completely abrogated tumor development by oncogenic 
NOTCH1, respectively. In addition, N-Me was also required for maintenance of NOTCH1 
induced leukemias as secondary deletion of one copy of N-Me in established tumors resulted 
in a marked delay in tumor progression and loss of two copies effectively abrogated 
leukemia propagation and leukemia initiating cell activity. These results are consistent with 
the well established quantitative effects of MYC expression in other tumor settings. Thus, 
loss of one copy of Myc has been shown to slow down intestinal tumorigenesis37 and 
homozygous deletion of Myc completely abrogates tumor development induced by loss of 
Apc in the gut38.
Several lines of evidence support a critical role for loss of Myc expression as the primary 
driver of the developmental and tumor phenotypes associated with N-me loss. In this regard, 
we observed marked reductions in Myc expression in developing T-cells from N-Me 
knockout mice and in T-ALL lymphoblast upon N-Me inactivation. Moreover, retroviral 
expression of Myc restored T-cell lymphopoiesis from N-Me deficient hematopoietic 
progenitors and rescued the defects in leukemia cell growth induced by secondary deletion 
on N-Me in NOTCH1-induced TALL cells. Finally, MYC inactivation has been associated 
with a global decrease in transcriptional activity with a particularly pronounced 
downregulation of genes involved in growth, proliferation and metabolism39–41, which were 
highly enriched in the gene expression signatures associated with N-Me loss in T-ALL.
The generation of the N-Me conditional knockout model presented here also served to 
analyze the specific role of this enhancer in transcriptional control. Thus, even though 
enhancer-promoter interactions have been implicated in the regulation of transcription by 
promoting the release of RNA polymerase II pausing in some cases42, deletion of N-Me in 
T-ALL lymphoblasts resulted in unloading of RNA polymerase II at the Myc transcription 
initiation site without any apparent increase in RNA polymerase II pausing.
Overall, the results shown here identify the N-Me regulatory sequence as a critical mediator 
of NOTCH1 induced MYC expression required for T-cell development and T-cell 
transformation and substantiates a pathogenic role for chromosomal duplications targeting 
this enhancer in the pathogenesis of T-ALL.
ONLINE METHODS
Cell lines
HPB-ALL and JURKAT were obtained from DSMZ. DAUDI and RAJI were obtained from 
American Type Culture Collection. Cells were cultured in standard conditions in RPMI 
media supplemented with 10% FBS and 1% Penicillin/Streptomycin.
NOTCH1 inhibition
We inhibited NOTCH1 in JURKAT cells with 250 nM DBZ ((S)-2-(2-(3,5-
Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-
yl) propanamide) (Syncom) for 48h as previously described43.
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Genomic analysis of primary T-ALL samples
A total of 160 T-ALL cases from adult and pediatric patients referred to St-Louis hospital, 
Paris, France were analyzed for copy-number abnormalities using array-comparative 
genomic hybridization with informed consent under the supervision of the Institutional 
Review Board of the Institut Universitaire d’Hématologie, Université Paris-Diderot. 
Sureprint G3 human CGH 180K, 244K, 400K or 1M arrays (Agilent technologies) were 
used and copy number alterations were identified using the Genomic Workbench software 
and the ADM-2 algorithm (Agilent Technologies) as previously described44.
T-ALL Oncogenic subtype was determined based on gene expression profiling as previously 
reported45, expression of T-ALL oncogene transcripts and presence of specific 
chromosomal translocations. NOTCH1 and FBXW7 mutations were analyzed as previously 
described46.
Chromatin immunoprecipitation (ChIP)
We performed chromatin immunoprecipitations using the Agilent Mammalian ChIP-on-chip 
chromatin immunoprecipitation protocol as described before12,47. Briefly, 108 HPB-ALL 
cells were fixed with formaldehyde in a final concentration of 1% for 10 minutes at room 
temperature. We quenched the crosslinking reaction with a 2.5 M glycine solution and the 
cells were then centrifuged, washed once with ice cold phosphate saline buffer and lysed. 
Cell nuclei were resuspended in lysis-buffer (10 mM Tris-HCl, pH 8.0; 100 mM NaCl; 1 
mM EDTA; 0.5 mM EGTA; 0.1% sodium deoxycholate; 0.5% N-lauroylsarcosine) and 
fragmented to a 150–300 bp size using a Bioruptor sonicator (Diagenode). We incubated 
fragmented chromatin)] overnight at 4°C with magnetic beads (Dynal) loaded with 1 mg of 
the following specific antibodies: anti-NOTCH C-20 (sc-6014; Santa Cruz Biotechnology); 
anti NOTCH1 Val1744 (#2421; Cell Signaling); anti p300 (sc-585; Santa Cruz 
Biotechnology); anti H3K4me1 (ab8895; Abcam) and anti H3K4me3 (ab1012; Abcam).
For RNApol II ChIP, N-Me (flox/flox); RosaTMCre (tg/+) tumor cells were treated in vitro 
with ethanol or tamoxifen, to induce N-Me deletion. 48 hours later, 107 cells from both 
conditions were processed the same way as described before, and the fragmented chromatin 
was incubated overnight at 4°C with magnetic beads loaded with 5mg of the RNApol II 
antibody (sc-899, Santa Cruz Biotechnology).
We washed chromatin-antibody-bead complexes seven times with RIPA buffer (50 mM 
Hepes-KOH, pH 7.6; 0.5 M LiCl; 1 mM EDTA; 1% Igepal and 0.7% sodium deoxycholate), 
and once with TE-buffer containing 50 mM NaCl. Then we eluted the chromatin from the 
beads with elution buffer (50 mM Tris-HCl, pH 8.0 10 mM EDTAand 1%SDS) and 
reversed the cross-link by incubation at 65°C overnight. We purified DNA fragments with 
phenol-chloroform and ethanol precipitation. We tested enrichment of specific 
immunoprecipitated DNA fragments by quantitative PCR as previously described12,47.
ChIP-seq
Chip-seq for NOTCH1 in HPB-ALL cells was performed using chromatin 
immunoprecipitates generated as described above and further fragmented to 100 bp average 
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size using a Covaris sonicator. All preparations of libraries for sequencing and the 
sequencing itself were performed according to the SOLiD3™ System protocols. For library 
preparation we performed adaptor ligation and purification, and the resulting DNA was 
amplified for 15 cycles. The libraries were then sequenced using 50 bp read lengths on a 
SOLiD3™ instrument (Life Technologies).
We recovered 17,530,449 reads and 9,591,524 unique reads (defined by a unique 
sequencing read start site) that mapped exactly once to the hg19 human genome from the 
NOTCH1 ChIP-seq library as well as 4,954,605 reads and 4,894,225 unique reads from the 
input control DNA library.
ChIP-seq and conservation analysis
We used HOMER (Hypergeometric Optimization of Motif EnRichment) software suite48 to 
estimate the ChIP-fragment density at each position in the human genome for HBPALL 
NOTCH1 ChIP-Seq data. We also analyzed ENCODE generated ChIP- seq data49 and the 
following publicly available ChIP-seq results: CUTLL1 NOTCH1 ChIP-seq (Gene 
Expression Omnibus GSM732903)18; CUTLL1 RBPJ ChIP-seq (Gene Expression Omnibus 
GSM732905)18; G4A2 NOTCH1 ChIP-seq (Gene Expression Omnibus GSM732916)18; 
G4A2 RBPJ ChIP-seq (Gene Expression Omnibus GSM732917)18.
We used MACS algorithm50 to call ChIP-Seq peaks and the top scoring intergenic peak was 
detected at chr8:130,180,065–130,180,972 (hg19), which aligns to the mouse genome 
(mm10) at chr15:63,255,515–63,256,347 (80.2% of bases, 100.0% of span).
The conservation track in Figure 1b shows a subset of the 100 vertebrates genomic sequence 
alignment as produced by the UCSC Genome Browser based on the MULTIZ algorithm 51.
Quantitative 3C analysis
We performed 3C analysis of chromatin interactions as previously described52 with some 
modifications. Briefly, HPB-ALL cells were crosslinked with formaldehyde in a final 
concentration of 1% for 10 minutes at room temperature. We quenched the crosslinking 
reaction with a 2.5 M glycine solution and the cells were then centrifuged, washed once with 
ice cold phosphate saline buffer and lysed. We digested cell nuclei overnight at 37°C with 
the HindIII restriction enzyme. After digestion the resulting fragments were highly diluted 
and ligated first 4 h at 16°C and then for 30 min at 37°C. After ligation the DNA was treated 
with proteinase K and de-crosslinked overnight at 65°C. We cleaned and purified the DNA 
fragments by phenol chloroform extraction and ethanol precipitation and resuspended them 
in 10 mM Tris pH 7.5. The resulting 3C template was used to perform quantitative PCR 
using primers flanking the HindIII restriction sites located in the regions of interest within 
the MYC locus and in the vicinity of the N-Me enhancer in 7300 quantitative PCR 
instrument (Applied Biosystems).
Luciferase reporter assays
We performed reporter assays using a pBV-Luc −2.5 kb MYC promoter luciferase 
construct21 alone and coupled with upstream human and mouse N-Me enhancer sequences 
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cloned in the forward and reverse orientation. In these assays, we electroporated in JURKAT 
cells with a Gene Pulser MXcell electroporator (Bio-Rad) using MYC luciferase reporter 
constructs together with a plasmid driving the expression of the Renilla luciferase gene 
(pCMV-Renilla) used as internal control and treated them with DMSO or DBZ (250 nM) to 
inhibit NOTCH signaling. We measured luciferase activity 48 h after electroporation with 
the Dual-Luciferase Reporter Assay kit (Promega).
Mice and animal procedures
All animals were maintained in specific pathogen-free facilities at the Irving Cancer 
Research Center at Columbia University Medical Campus. Animal procedures were 
approved by the Columbia University Institutional Animal Care and Use Committee.
To generate N-Me conditional knockout mice, we introduced LoxP sites at mouse genomic 
(GRCm38/mm10) positions 63.255.283 and 63.256.404 flanking the mouse N-Me enhancer 
together with a neomycin selection cassette flanked by Frt sites by homologous 
recombination in C57BL/6 embryonic stem cells. We generated chimeras in C57BL/6 albino 
blastocysts using three independent targeted embryonic stem cell clones identified by PCR 
analysis and verified by Southern blot. We verified germline transmission in the offspring of 
highly chimeric male mice crossed with C57BL/6 albino females. To remove the neomycin 
selection cassette we crossed mice harboring the targeting construct with a Flp germline 
deleter line (B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ, the Jackson Laboratory). To 
generate mice carrying a N-Me deletion we first crossed mice harboring this resulting 
conditional N-Me targeted allele with a Cre germline deleter line (B6.C-Tg(CMV-
cre)1Cgn/J, the Jackson Laboratory) and then crossed the resulting mice with wild type 
C57BL/6 animals to breed out the CMV-cre allele. To generate conditional inducible N-Me 
knockout mice we bred animals harboring the conditional N-Me targeted allele with 
ROSA26TMCretg/+ mice, which express a tamoxifen-inducible form of the Cre recombinase 
from the ubiquitous Rosa26 locus53. Phenotypic characterization of N-Me knockout mice 
included male and female mice and isogenic age and gender matched controls.
Mammary epithelial cell isolation
To determine the specific estrus stage and thus the concomitant mammary gland 
developmental phase, we analyzed female mice for the presence of leukocytes, cornified 
epithelial cells, and nucleated epithelial cells in vaginal smears as previously described54. To 
purify mammary epithelial cells (MECs), mammary glands were dissected, mechanically 
disrupted and digested using a digestion solution composed by DMEM-F12, 100 units/mL 
Penicillin-Streptomycin, 2mg/mL collagenase-A and 100 units/mL hyaluronidase, for four 
hours at 37°C. After digestion we washed mammary epithelial cells in Phosphate buffered 
saline solution and recovered them by centrifugation.
Mammary gland whole mount preparations and carmin red staining
For whole mount preparations we dissected mouse mammary glands, fixed them in 4% 
paraformaldehyde for 1 hour and stained them with carmine red (C1022, Sigma-Aldrich) 
overnight at room temperature. Following carmin red staining we dehydrated the stained 
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tissues in increasing concentrations of ethanol (70, 95 and 100%) and ultimately fixed them 
in xylene.
Immunohistochemistry
We performed immunohistochemical stainings following standard protocols using 
antibodies against Ki67 (15580, Abcam), phosphorylated-histone H3 (9701, Cell Signaling 
Technology) and Cleaved Caspase 3 (9664, Cell Signaling Technology) were used.
Generation of NOTCH1 induced leukemias
To generate NOTCH1-induced T-ALL tumors in mice, we performed retroviral transduction 
of bone marrow cells enriched in Lineage negative cells isolated from female mice using 
magnetic beads (Lineage Cell Depletion Kit, Miltenyi Biotec) with an activated form of the 
NOTCH1 oncogene (ΔE-NOTCH1)10 and transplanted them via intravenous injection into 
lethally irradiated female isogenic recipients as previously described55.
Flow cytometry analysis of hematopoietic populations
Single-cell suspensions of total bone marrow cells from 6-week old wild-type and N-Me 
heterozygous and homozygous knockout littermates were prepared by crushing the leg 
bones and passing cells through a 40 μm filter. Single-cell suspensions of thymocytes were 
obtained by pressing one thymic lobe through a 40 μm filter. For flow cytometry based 
analysis of bone marrow stem and progenitor populations, and discrete stages of T cell 
development, cells were stained with anti-mouse fluorochrome-conjugated antibodies as 
follows (clone names are provided in brackets). CD8α PE-Cy7 (53-6.7), CD16/CD32 Alexa 
Fluor 700 (93), CD41 PE-Cy7 (eBioMWReg30), CD44 PerCP-Cy5.5 (IM7), CD48 eFluor 
450 (HM48-1), CD105 eFluor 450 (MJ7/18), CD117 PerCP-eFluor 710 (2B8), Ly6A/E 
(Sca-1) PE-Cy7 (D7), biotin-CD11b (M1/70), -Ly-6G (Gr1; RB6-8C5), -NK1.1 (PK136), -
Ter119 (TER119), -CD8α (53-6.7), -CD4 (GK1.5), -CD19 (eBio1D3), -CD45R (B220; 
RA3-6B2) and Streptavidin PE were purchased from eBioscience. CD150 APC, CD150 PE 
(both TC15-12F12.2) and Ly-6A/E (Sca-1) PE (D7) were purchased from BioLegend. CD4 
APC-Cy7 (GK1.5), CD25 APC-Cy7 (PC61) and Streptavidin APC-Cy7 were purchased 
from BD Biosciences. Flow cytometry analysis of the different populations [HSCs and bone 
marrow progenitor subsets: KLS total HSCs (Lin− CD117+ Sca-1+), LT-HSC (Lin− CD117+ 
Sca-1+ CD150+ CD40−), ST-HSC (Lin− CD117+ Sca-1+ CD150+ CD40+), MPP (Lin− 
CD117+ Sca-1+ CD150− CD40+/−), CMP total (Lin− CD117+ Sca-1−), CLP (Lin− CD117+ 
Sca-1int CD135+), MkP (Lin− CD117+ Sca-1− CD150+ CD41+) and GMP (Lin− CD117+ 
Sca-1− CD150− CD41− CD16/32+); T cell immature subsets in the thymus: ETP (Lin− 
CD117hi CD44+), DN1 (Lin− CD44+ CD25−), DN2 (Lin− CD44+ CD25+), DN3 (Lin− 
CD44− CD25+) and DN4 (Lin− CD44− CD25−)] was performed using a BD LSRII and a BD 
LSRFortessa cell analyzer (BD Bioscience).
For the analysis of B cell differentiation in bone marrow, we performed surface staining 
with the following anti-mouse fluorochrome and biotin-conjugated antibodies: B220-PE-
Cy5 (BD Pharmingen-553091), CD19-biotin (eBioscience-13-0193), CD25-APC-Cy7 (BD 
Pharmingen-557658), IgM-APC (eBioscience-17-5790), and IgD-PE 
(eBioscience-12-5993). CD19-biotin antibody was detected using PE-Cy7-conjugated 
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streptavidin (eBiosciences-25-4317). Flow cytometry analysis of the different populations 
[preproB (B220+ CD19−), proB (B220+ CD19+ CD25− IgM− IgD−), preB (B220+ CD19+ 
CD25+ IgM− IgD−) and immature B cells (B220+ CD19+ CD25− IgM+ IgD−)] was 
performed using a FACSCanto Flow Cytometer (BD Bioscience).
For the analysis of T cell populations in spleen and lymph nodes we collected tissues from 
6-week old wild-type and N-Me knockout littermates and processed through a 70 μm mesh 
to obtain single cell suspensions. We removed red cells in spleen samples by incubation with 
red blood cell lysis buffer (155 mM NH4Cl; 12 mM KHCO3; 0.1 mM EDTA) 5 minutes at 
room temperature. We stained cells with APC-conjugated antibodies against mouse CD4 
(BD Pharmingen-553051) and PE-conjugated antibodies against mouse CD8a (BD 
Pharmingen-553032).
For the analysis of megakaryocytes in bone marrow and spleen and platelets in peripheral 
blood, we collected tissues from 6-week old wild-type and N-Me heterozygous and 
homozygous knockout littermates and processed through a 70 μm mesh to obtain single cell 
suspensions. We removed red cells samples by incubation with red blood cell lysis buffer 
(155 mM NH4Cl; 12 mM KHCO3; 0.1 mM EDTA) 5 minutes at room temperature. We 
stained cells with a FITC-conjugated antibody against mouse CD41 
(eBioscience-11-0411-81). Flow cytometry analyses were performed in a FACSCanto flow 
cytometer (BD Biosciences).
Bone marrow reconstitution experiments
We isolated bone marrow lineage negative cells from N-Me+/+, N-Me+/− and N-Me−/− 
CD45.2 expressing mice using magnetic beads (Lineage Cell Depletion Kit, Miltenyi 
Biotec) following the manufacturer’s guidelines, and then transplanted into lethally 
irradiated CD45.1 C57BL6 female mice (Taconic). 6 weeks post-transplant, hematologic 
reconstitution of myeloid lineage, B-cell lineage and T-cell lineage was assessed by 
peripheral blood staining with the specific antibodies mentioned above, and analyzed in a 
FACSCanto flow cytometer using FACSDiva (BD Biosciences).
For the Myc rescue experiment in vivo we isolated bone marrow lineage negative cells from 
N-Me−/− mice as before, infected them with either MSCV-IRES-mCherry or MSCV-Myc-
IRES-mCherry retroviruses and then transplanted into male and female NRG (NOD.Cg-
Rag1 tm1Mom Il2rg tm1Wjl/SzJ) mice (The Jackson Laboratory). We assessed T-cell 
lineage reconstitution 3 weeks post-transplant in peripheral blood by flow cytometry 
quantitation of cells stained with specific antibodies against CD4-APC (BD 
Pharmingen-553051) and CD8-FITC (BD Pharmingen-553030) in a BD LSRFortessa flow 
cytometer (BD Biosciences) using FACSDiva software (BD Biosciences).
Flow cytometry analysis of Myc expression
We collected cells from the thymi of 6-week old male and female wild type and N-Me 
knockout mice and performed surface membrane stainings using the following antibodies: 
CD3-Alexa Fluor 488 (BD Pharmingen-557666), CD8a-PE-Cy7 (eBioscience-53-6.7), 
CD44-PerCP-Cy5.5 (eBioscience-IM7), CD25-APC-Cy7 (BD Pharmingen-557658) and 
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CD4-APC (BD Pharmingen-553051). After surface staining we fixed the cells and 
permeabilized them with BD Cytofix/Cytoperm solution (BD Biosciences), washed them 
with BD Perm/Wash buffer (BD Biosciences), and stained them with a mouse anti-Myc 
antibody (sc-40, Santa Cruz) and an Alexa Fluor 546-conjugated donkey anti-mouse IgG 
antibody (A11036, Invitrogen). We analyzed the intracellular levels of Myc in a FACSCanto 
flow cytometer (BD Biosciences) using FACSDiva software (BD Biosciences).
Microarray gene expression profiling
We isolated and snap froze spleen samples from of N-Me conditional knockout NOTCH-
induced T-ALL bearing mice 40 hours after treatment with vehicle only (corn oil, SIGMA) 
or tamoxifen (3 mg/Kg in corn oil, SIGMA) administered by intraperitoneal injection. RNA 
was isolated, labeled and hybridized to the MouseRef-8 v2.0 Expression BeadChip 
(Illumina) using standard procedures. Raw gene expression data were log2 transformed and 
quantile-normalized using MATLAB. Differentially expressed transcripts were identified by 
t-test. Enrichment of MYC signature genes56,57 were analyzed by GSEA using the t-test 
metric and 10,000 permutations of the gene list58. Differentially expressed genes induced by 
tamoxifen deletion of the N-Me enhancer (P < 0.001, fold change >1.5) were analyzed for 
functional annotation enrichment using DAVID Bioinformatics web tools59.
Quantitative real time PCR
We performed reverse transcription reactions with the ThermoScript RT-PCR system 
(Invitrogen) and analyzed resulting complementary DNA products by quantitative real-time 
PCR (FastStart Universal SYBR Green Master Mix (Roche) using a 7300 Real-Time PCR 
System (Applied Biosystems). Relative expression levels were normalized using Gapdh as a 
reference control.
Western Blotting
Western blot was performed using standard procedures. Antibodies against Myc (sc-764, 
Santa Cruz), and Gapdh (5174, Cell Signaling) were used.
Statistical analyses
We performed statistical analysis by Student’s t-test. We assumed normality and equal 
distribution of variance between different groups analyzed. Survival in mouse experiments 
was represented with Kaplan-Meier curves and significance was estimated with the log-rank 
test (Prism GraphPad). We analyzed serial limited dilution leukemia-initiating cell data 
using the ELDA software60.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Identification of N-Me, a NOTCH-bound MYC enhancer recurrently amplified in T-ALL. 
(a) NOTCH1 ChIP-seq binding occupancy profile in the MYC locus in HPB-ALL T-ALL 
cells and schematic representation of chromosome 8q24 focal amplifications (red bars) 
found in human T-ALL. (b) NOTCH1 and RBPJ ChIP-seq binding in T-ALL cells and 
multispecies sequence conservation along a 20 kb window encompassing the HPB-ALL 
MYC +1.47 Mb NOTCH1 binding site. The green blocks at the bottom represent pairwise 
aligned regions with the height of the bars indicating the average base pair alignment score 
with the human sequence. (c) NOTCH1 ChIP-seq binding occupancy profile in the Myc 
locus in G4A2 mouse T-ALL cells. (d) ChIP analysis of NOTCH1, P300, H3K4me1 and 
H3K4Me3 in HPB-ALL T-ALL cells. (e) CTCF, H3K27ac and H3K4me1 ChIP-seq 
occupancy in DND-41 T-ALL cells along a 10 kb window containing the MYC +1.47 Mb 
NOTCH1 binding site. (f) ChIP-seq analysis of H3K27ac along the N-Me sequence in 
DND-41 T-ALL cells, B-cells (CD20+), monocytes (CD14+), embryonic stem cells (H1-
hESC), endothelial cells (HUVEC) and osteoblasts. Y axis in ChIP-seq plots indicates 
fragment density in counts per 10 million.
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Figure 2. 
Functional characterization of the N-Me enhancer. (a) NOTCH1 ChIP-seq binding 
occupancy profile in the MYC locus in HPB-ALL T-ALL cells along with 3C quantitative 
PCR analysis of the interaction frequency between DNA sequences flanking a HindIII 
restriction site in the MYC promoter with indicated sites located 3′ in the MYC locus and in 
the vicinity of the MYC +1.47 Mb NOTCH1 binding site. PCR signal is normalized to 
bacterial artificial chromosome (BAC) templates. (b) Luciferase reporter activity and 
response to inhibition of NOTCH with the DBZ γ-secretase inhibitor in JURKAT T-ALL 
cells of a MYC promoter construct (MYC Luc), a MYC promoter plus human N-Me enhancer 
in + orientation (hN-Me(+) MYC Luc) and a MYC promoter plus human N-Me enhancer in – 
orientation (hN-Me(−) MYC Luc) construct. Data from five technical replicates is shown. (c) 
Luciferase reporter activity in JURKAT T-ALL cells of a MYC promoter construct (MYC 
Prom-Luc), a MYC promoter plus human N-Me enhancer in + orientation (hN-Me(+) MYC 
Luc), and a MYC promoter plus human N-Me enhancer in – orientation (hN-Me(−) MYC 
Luc), both using the wild type hN-Me sequence or a hN-Me sequence with mutations in 7 
RBPJ binding sites. Data from five technical replicates is shown. (d) Luciferase reporter 
activity in JURKAT T-ALL cells of a MYC promoter construct (MYC Luc), a MYC promoter 
plus human N-Me enhancer in + orientation (hN-Me(+) MYC Luc), and a MYC promoter 
plus a tandem duplication of the human N-Me enhancer in + orientation (hN-Me(++) MYC 
Luc). Data from five technical replicates is shown. (e) Luciferase reporter activity and 
response to inhibition of NOTCH with the DBZ γ-secretase inhibitor in JURKAT TALL 
cells of a MYC promoter construct (MYC Luc), a MYC promoter plus mouse N-Me enhancer 
in + orientation (mN-Me(+) MYC Luc) and a MYC promoter plus mouse N-Me enhancer in 
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– orientation (mN-Me(−) MYC Luc). Data from five technical replicates is shown. (f) 
Luciferase reporter activity in JURKAT T-ALL cells of a MYC promoter construct (MYC 
Luc), a MYC promoter plus mouse N-Me enhancer in + orientation (mN-Me(+) MYC Luc), 
and a MYC promoter plus mouse N-Me enhancer in – orientation (mN-Me(−) MYC Luc), 
both using the wild type mN-Me sequence or a mN-Me sequence with mutations in 11 RBPJ 
binding sites. Data from five technical replicates is shown. Bar graphs in b–f indicate mean 
values and error bars represent s.d. P values were calculated using the two-tailed Student’s t-
test: *** P ≤ 0.005. Y axis in ChIP-seq plots indicates fragment density in counts per 10 
million.
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Figure 3. 
Histological analysis of the thymus in N-Me knockout mice. (a–d) Thymus morphology (a), 
weight (b), cellularity (c) and histology (d) in 6-week old N-me wild type (N-Me+/+) 
heterozygous (N-Me+/−) and knockout (N-Me−/−) mice (n = 3 per genotype). (e) 
Immunohistochemical analysis of Ki67, phopho-histone H3 and cleaved caspase 3 
expression in thymi from 6-week old N-me wild type (N-Me+/+), heterozygous (N-Me+/−) 
and knockout (N-Me−/−) mice. Scale bar in (a) indicates 1 cm. Scale bar in (d) indicates 100 
μm. Scale bar in (e) indicates 200 μm. Representative images of three independent samples 
are shown in d,e. P values were calculated using the one-tailed Student’s t-test:: * P ≤ 0.05; 
*** P ≤ 0.005.
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Figure 4. 
Characterization of T-cell development in N-Me knockout mice. (a) Representative flow 
cytometry plots of thymocyte populations stained with anti-CD4 and anti-CD8 in N-me wild 
type, heterozygous and knockout mice. Percentage populations are indicated in each 
quadrant. (b,c) Quantification of intrathymic T-cell populations in N-Me wild type, 
heterozygous and null mice in absolute numbers. (d,e) Quantification of intrathymic T-cell 
populations in N-Me wild type, heterozygous and null mice in relative numbers. (f) 
Quantification of intracellular Myc levels in immature T-cell populations from N-Me wild 
type and knockout mice as measured by flow cytometry. (g) Myeloid, B-cell and T-cell 
levels in peripheral blood of CD45.1 lethally irradiated mice 6 weeks after transplantation 
with CD45.2 bone marrow progenitors from N-Me knockout mice. (h) T-cell levels in 
peripheral blood of NRG mice 3 weeks after transplantation with bone marrow progenitors 
from N-Me knockout mice infected with retroviruses expressing mCherry (Empty Cherry) 
or Myc plus mCherry (Myc Cherry). Bar graphs in (b–d and g–h) indicate mean values 
across triplicate samples and error bars represent s.d. P values in were calculated using the 
two-tailed Student’s t-test: # P = 0.07; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.005.
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Figure 5. 
Analysis of T-ALL tumor initiation in N-Me knockout mice. (a) Representative flow 
cytometry plots of peripheral blood stained with anti-CD4 and anti-CD8 from mice 
transplantated with ΔE-NOTCH expressing N-Me wild type, heterozygous or knockout 
progenitors 3 weeks post-transplant. Percentage populations are indicated in each quadrant. 
Quantification of CD4 CD8 double positive population is shown on the right (n = 6 per 
genotype). (b) Representative blood smear preparations from mice transplanted with ΔE-
NOTCH expressing N-Me wild type, heterozygous or knockout progenitors at 6 weeks post-
transplant. Quantification of CD4 CD8 double positive population is shown on the right (n = 
6 per genotype). (c) Kaplan-Meier survival curves of mice transplanted with ΔE-NOTCH-
infected N-Me wild type, heterozygous or knockout hematopoietic progenitors (n = 6 per 
genotype). Bar graphs in (a) indicate mean values and error bars represent s.d. Scale bar in 
(b) indicates 100μm. P values in (a) were calculated using the two-tailed Student’s t-test: 
*** P ≤ 0.005. P values in (c) were calculated using the log-rank test: ** P ≤ 0.01; *** P ≤ 
0.005.
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Figure 6. 
Analysis of leukemia maintenance in N-Me knockout cells. (a) Kaplan-Meier survival 
curves of mice harboring N-Me wild type Rosa26TMCre NOTCH1 induced leukemias 
treated with vehicle only (n = 10) or tamoxifen (n = 9). (b) Kaplan-Meier survival curves of 
mice harboring N-Me conditional heterozygous Rosa26TMCre NOTCH1 induced leukemias 
treated with vehicle only (n = 10) or tamoxifen (n = 10). (c) Kaplan-Meier survival curves of 
mice harboring N-Me conditional homozygous knockout Rosa26TMCre NOTCH1 induced 
leukemias treated with vehicle only (n = 10) or tamoxifen (n = 10). (d) ChIP analysis of 
RNApol II binding at the Myc locus 48 hours after treating N-Meflox/flox; RosaTMCretg/+ 
tumor cells in vitro with ethanol or 4-OH-tamoxifen, to induce N-Me deletion. Data from 
three technical replicates is shown. (e) Quantitative RT-PCR analysis of Myc expression in 
tumor cells isolated from N-Me conditional knockout-leukemia bearing mice treated with 
vehicle only (n = 4) or tamoxifen (n = 5) in vivo. (f) Western-blot analysis of Myc 
expression in tumor cells isolated from N-Me conditional knockout-leukemia bearing mice 
treated with vehicle only (n = 3) or tamoxifen (n = 3) in vivo. (g) Representative DNA 
content analysis and quantification of cell proliferation (S+G2/M fraction) of N-Me 
conditional knockout Rosa26TMCre NOTCH1 induced leukemias treated with vehicle only 
(n = 4) or tamoxifen (n = 5) in vivo. (h) Proliferation curve of 4-OH-tamoxifen treated N-
Meflox/flox; RosaTMCretg/+ tumor cells infected with an MSCV-Empty cherry virus or an 
MSCV-Myc cherry virus, relative to ethanol treated controls. (i) Heat map representation of 
the top 50 differentially expressed Entrez Genes genes (P <0.001) between control and 
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tamoxifen treated N-Me conditional knockout Rosa26TMCre NOTCH1 induced leukemias. 
The scale bar shows color coded differential expression with red indicating higher levels and 
blue lower levels of expression. (j) GSEA analysis of genes regulated by MYC in vehicle 
only versus tamoxifen treated N-Me conditional knockout Rosa26TMCre NOTCH1 induced 
leukemia cells in vivo. Bar graphs in (d,e,g) indicate mean values and error bars represent 
s.d. P values in (a–c) were calculated using the log-rank test: *** P ≤ 0.005. P values in (d, 
e, g) were calculated using the two-tailed Student’s t-test: *** P ≤ 0.005.
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